We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02881853
Previous Study | Return to List | Next Study

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02881853
First Posted: August 29, 2016
Last Update Posted: July 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
ICON Early Phase Services, LLC
Information provided by (Responsible Party):
Xencor, Inc.
  Purpose
This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.

Condition Intervention Phase
Healthy Volunteers Atopic Disease Drug: XmAb7195 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Further study details as provided by Xencor, Inc.:

Primary Outcome Measures:
  • Bioavailability of SC XmAb7195 after 4 once-weekly doses as measured by the ratio of dose-normalized SC XmAb7195 area under the concentration-time curve (AUC) to dose-normalized IV XmAb7195 AUC. [ Time Frame: Date of randomization up to Day 50 ]

Secondary Outcome Measures:
  • Cmax, Maximum observed serum concentration [ Time Frame: Date of randomization up to Day 50 ]
  • Time at which Cmax was observed [Tmax] [ Time Frame: Date of randomization up to Day 50 ]
  • Area Under the Curve (AUC) [ Time Frame: Date of randomization up to Day 50 ]
  • Terminal elimination half-life [t1/2] [ Time Frame: Date of randomization up to Day 50 ]
  • Total body or systemic clearance [CL] [ Time Frame: Date of randomization up to Day 50 ]
  • Apparent volume of distribution at steady state [Vss] [ Time Frame: Date of randomization up to Day 50 ]
  • Immunogenicity of SC XmAb7195 and IV XmAb7195 as measured by incidence of development of anti-XmAb7195 antibody after 4 once-weekly doses [ Time Frame: Date of randomization up to Day 50 ]

Enrollment: 57
Actual Study Start Date: August 17, 2016
Study Completion Date: February 24, 2017
Primary Completion Date: February 24, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A1
XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
Drug: XmAb7195
Experimental: Part A2
XmAb7195 for SC injection; dose level 1; 4 once weekly doses
Drug: XmAb7195
Experimental: Part A3
XmAb7195 for SC injection; dose level 2; 4 once weekly doses
Drug: XmAb7195
Experimental: Part A4
XmAb7195 for SC injection; dose level 3; 4 once weekly doses
Drug: XmAb7195
Experimental: Part A5
XmAb7195 for SC injection; dose level 4; 4 once weekly doses
Drug: XmAb7195
Experimental: Part B6
XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
Drug: XmAb7195 Drug: Placebo
Experimental: Part B7
XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
Drug: XmAb7195 Drug: Placebo
Experimental: Part B8
XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
Drug: XmAb7195 Drug: Placebo
Experimental: Part B9
XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
Drug: XmAb7195 Drug: Placebo

Detailed Description:
The study will be divided into 2 parts. Part A will be an open-label, parallel group, BA study evaluating 4 once-weekly doses of IV XmAb7195 or SC XmAb7195 in healthy subjects. Each of 5 treatment groups will consist of 6 subjects. Part B will commence following the completion of Part A and will be a randomized, double-blind, placebo-controlled, MAD study evaluating 4 once weekly doses of SC XmAb7195 in healthy subjects and/or subjects with atopic disease. Each treatment group will consist of 8 subjects randomized 3:1 to XmAb7195:placebo Subjects in both parts of the study will be followed for at least 28 days after their last dose.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All Subjects:

  • Male or female between 18 to 60 years of age (inclusive at the time of screening).
  • Total body weight 50.0 to 100.0 kg, and body mass index (BMI) 19.0 to 35.0 kg/m2 (inclusive, at screening).
  • Women can be of either childbearing or non-childbearing potential.
  • Must be healthy with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease that would pose a risk to subject or interfere with the study evaluation, procedures, or completion as assessed by the Investigator.

Subjects with Atopic Disease Only (Part B):

  • Allergen skin test reactivity of ≥ 5 mm wheal greater than saline control to any 2 of the following 5 allergens: D. pteronyssinus, D. farina, ragweed, Virginia live oak, and mountain cedar within 21 days prior to dosing.
  • Sufficient clinical control of subject's atopic disease such that, in the opinion of the Investigator, the subject is unlikely to require substantial changes in therapy medication for the duration of the trial and unlikely to require the addition of an exclusionary medication

Exclusion Criteria:

  • Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases, or disorders that would pose a significant risk to subject's safety or significantly interfere with the study evaluation, procedures, or completion as assessed by the Investigator.
  • Subjects with platelet count < 150 k/uL at screening or at the time of initial admission.
  • Subjects with peak expiratory flow rate < 400 L/min for males and < 350 L/min for females.
  • Subjects with conditions associated with high risk of bleeding such as: past history of intracranial or gastrointestinal bleeding, hemorrhagic condition including hereditary or acquired bleeding, or coagulation disorder.
  • Subjects with history of any clinically significant cardiovascular event such as: myocardial infarction, acute coronary syndrome, stroke, pulmonary embolism, and/or deep venous thrombosis.
  • Subjects who do not agree to use medically acceptable methods of contraception (as defined in the protocol).
  • Subjects who are pregnant or breast feeding, or planning to become pregnant within 30 days of last dose of XmAb7195.
  • Subjects who have used prescription drugs within 28 days prior to randomization with the following exceptions for Part B subjects with atopic disease:

    1. Intranasal corticosteroids for allergic symptoms if the dose has been stable for 14 days prior to randomization.
    2. Inhaled short acting beta agonist (SABA) therapy for bronchospasm if dosing has been stable for 14 days prior to randomization.
    3. No other prescription drugs are allowed unless agreed as not clinically relevant by the Investigator and Sponsor.
  • Subjects who have had an asthma exacerbation requiring hospitalization within the 1 year prior to randomization or having required oral corticosteroids within the 6 months prior to randomization.
  • Subjects with poorly controlled asthma defined as SABA > 6 times/day on any day within the 4 weeks prior to randomization.
  • Subjects who have used any of the following medications within the 3 months prior to randomization: oral or inhaled corticosteroids, long acting beta agonists (LABAs), leukotriene receptor antagonists (LTRAs), or any other asthma controller medication (occasional SABA use is allowed).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02881853


Locations
United States, Texas
ICON Early Phase Services, LLC
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Xencor, Inc.
ICON Early Phase Services, LLC
Investigators
Principal Investigator: Emanuel P DeNoia, MD ICON Early Phase Services, LLC
  More Information

Responsible Party: Xencor, Inc.
ClinicalTrials.gov Identifier: NCT02881853     History of Changes
Other Study ID Numbers: XmAb7195-02
First Submitted: August 24, 2016
First Posted: August 29, 2016
Last Update Posted: July 11, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Xencor, Inc.:
healthy
atopic